Abstract
Skin banks are tissue establishments dedicated to the procurement, processing, and distribution of human-derived skin bioproducts for clinical purposes. A skin bank must observe national/international guidelines and perform standardized procedures to ensure tissue traceability and biological safety in all processing stages and to avoid potential biological contamination. In order to minimize the risk of transmission of pathogenic agents, rigorous donor screening, extensive microbiological and serological tests for transmissible diseases are performed before tissue procurement; in addition, careful quality controls are conducted during tissue manipulation. Skin bank organization is complex, including multiple fully trained work teams dedicated to either the harvesting or the processing phases, employed in research laboratories or in the distribution activity and application in hospital/clinical setting. All dedicated personnel require constant training and updating. Many different types of skin bioproducts can be released from a skin bank, depending on the processing and storage method (deep-freezing/cryopreservation/glycerol-preservation/lyophilization), tissue viability, graft thickness, and the post-processing tissue preparation (meshed-expansion or not). Skin bank bioproducts have been used as a temporary dressing or, in burns, as definitive grafts in several types of loss of substance, for different clinical purposes: promotion of re-epithelization, healing time reduction, pain control, and protection of fragile subcutaneous structures (cartilage, tendons, bones, and nerves). Though a great variety of dermal matrices and skin equivalents are available, synthetic and semisynthetic, viable human skin allografts are still considered the most physiological alternative to autologous skin in burns and hard-to-heal wounds. The demand for human-derived skin bioproducts continues to be a reason for the existence of skin banks.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
McCauley RL. The skin bank. Total burn care. 1st ed. Philadelphia, PA: Saunders; 1996. p. 159–63.
Mericka P. Brief history of the tissue bank, Charles University Hospital, Hradec Kralove, Czech Republic. Cell Tissue Bank. 2000;1(1):17–25.
Hermans MHE. Preservation methods of allografts and their (lack of) influence on clinical results in partial thickness burns. Burns. 2011;37(5):873–81.
De SK, Reis ED, Kerstein MD. Wound treatment with human skin equivalent. J Am Podiatr Med Assoc. 2002;92(1):19–23.
Kearney JN. Guidelines on processing and clinical use of skin allografts. Clin Dermatol. 2005;23(4):357–64.
Fimiani M, Pianigiani E, Di Simplicio FC, et al. Other uses of homologous skin grafts and skin bank bioproducts. Clin Dermatol. 2005;23(4):396–402.
Pianigiani E, Tognetti L, Ierardi F, et al. Il derma acellulare liofilizzato. Hi-Tech Dermo. 2016;3:17–20.
Pianigiani E, Tognetti L, Ierardi F, et al. Assessment of cryopreserved donor skin viability: the experience of the regional tissue bank of Siena. Cell Tissue Bank. 2016;17(2):241–53.
Tognetti L, Pianigiani E, Ierardi F, et al. Current insights into skin banking: storage, preservation and clinical importance of skin allografts. J Biorepos Sci Appl Med. 2017;5:1–16.
European Directorate for the Quality of Medicines & Health Care (EDQM). Guide to the quality and safety of tissues and cells for human application. Conseil of Europe, Strasbourg (France); 2017. 3rd ed.
Official Journal of the European Union. Directive 2004/23/EC of the European Parliament and Council on quality and safety standards for the donation, procurement, testing, processing, preservation, storage and distribution of human tissues and cells. Official Journal of the European Union; 2004. Available from: http://eur-lex.europa.eu/Lex-UriServ/LexUriServ.do?uri=OJ:L:2004:102:0048:0058:en:PDF. Accessed June 5, 2017.
Commission Directive 2006/17/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards certain technical requirements for the donation, procurement and testing of human tissues and cells. Available from: http://eur-lex.europa.eu/legalcontent/EN/TXT/?uri=celex%3A32006L0017. Accessed June 5, 2017.
Commission Directive 2006/86/EC implementing Directive 2004/23/EC of the European Parliament and of the Council as regards traceability requirements, notification of serious adverse reactions and events and certain technical requirements for the coding, processing, preservation, storage and distribution of human tissues and cells. Available from: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=celex%3A32006L0086. Accessed June 5, 2017.
European Commission [Homepage on the Internet]. EudraLex—Volume 4—Good Manufacturing Practice (GMP) guidelines; 2010 [updated December, 2010]. Available at: https://ec.europa.eu/health/documents/eudralex/vol-4_en. Accessed June 29, 2017.
Center for Biologics Evaluation and Research—CBER. HCT/P’s Regulated under 21 CFR 1271.3(d)(1) and Section 361 of the PHS Act.
Wright C, Velickovic Z, Brown R, et al. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (CGMP) for human blood and blood components, human tissues and human cellular therapy products. Pathology. 2014 Apr;46(3):177–83.
Kagan RJ, Robb EC, Plessinger RT. Human skin banking. Clin Lab Med. 2005;25(3):587–605.
Pianigiani E, Ierardi F, Cherubini F, et al. Skin bank organization. Clin Dermatol. 2005;23(4):353–6.
Pianigiani E, Ierardi F, Fimiani M. Importance of good manufacturing practices in microbiological monitoring in processing human tissues for transplant. Cell Tissue Bank. 2013;14(4):601–7.
Gaucher S, Elie C, Verola O, Jarraya M. Viability of cryopreserved human skin allografts: effects of transport media and cryoprotectants. Cell Tissue Bank. 2012;13(1):147–55.
Linee guida per il prelievo, la processazione e la distribuzione dei tessuti a scopo di trapianto—Centro Nazionale per i Trapianti (CNT); 2015. Available from: http://www.trapianti.salute.gov.it. Accessed January 2, 2017.
Vicentino M, Rodriguez G, Saldias M, Alvarez I. Guidelines to implement quality management systems in microbiology laboratories for tissue banking. Transplant Proc. 2009;41(8):3481–4.
Pianigiani E, Ierardi F, Cuciti C, Brignali S, Oggioni M, Fimiani M. Processing efficacy in relation to microbial contamination of skin allografts from 723 donors. Burns. 2010;36(3):347–51.
Pianigiani E, Risulo M, Ierardi F, et al. Prevalence of skin allograft discards as a result of serological and molecular microbiological screening in a regional skin bank in Italy. Burns. 2006;32(3):348–51.
Saegeman VS, Ectors NL, Lismont D, Verduyckt B, Verhaegen J. Short- and long-term bacterial inhibiting effect of high concentrations of glycerol used in the preservation of skin allografts. Burns. 2008;34(2):205–11.
Gaucher S, Jarraya M. Cryopreserved human skin allografts: efficacy and viability. Burns. 2014;40(3):526–7.
Cleland H, Wasiak J, Dobson H, et al. Clinical application and viability of cryopreserved cadaveric skin allografts in severe burns: a retrospective analysis. Burns. 2014;40(1):61–6.
Pianigiani E, Taddeucci P, Mancini S, Miracco C. Wound healing in leg ulcers treated by combined skin allograft and autograft. J Invest Dermatol. 2001;117:544.
Towler MA, Rush EW, Richardson MK, Williams CL. Randomized, prospective, blinded-enrollment, head-to-head venous leg ulcer healing trial comparing living, bioengineered skin graft substitute (Apligraf) with living, cryopreserved, human skin allograft (TheraSkin). Clin Podiatr Med Surg. 2018;35(3):357–65.
Mosti G, Mattaliano V, Picerni P, et al. Skin grafting in the treatment of hard-to-heal leg ulcers. Italian Journal of Wound Care. 2018;2(1):1–7.
Khoo TL, Halim AS, Mat Saad AZ, Dorai AA. The application of glycerol-preserved skin allograft in the treatment of burn injuries: an analysis based on indications. Burns. 2010;36(8):97–904.
Leon-Villapalos J, Eldardiri M, Dziewulski P. The use of human deceased donor skin allografts in burn care. Cell Tissue Bank. 2010;11(1):99–104.
Kua EH, Goh CQ, Ting Y, Chua A, Song C. Comparing the use of glycerol preserved and cryopreserved allogenic skin for the treatment of severe burns: differences in clinical outcomes and in vitro tissue viability. Cell Tissue Bank. 2012;13(2):269–79.
Ferrando PM, Balmativola B, Cambieri I, et al. Glycerolized reticular dermis as a new human acellular dermal matrix: an exploratory study. PLOS One. 2016;11(2):e0149124.
Rooney P, Eagle M, Hogg P, et al. Sterilisation of skin allograft with gamma irradiation. Burns. 2008;34(5):664–73.
Jansen LA, De Caigny P, Guay NA, et al. The evidence base for the acellular dermal matrix AlloDerm: a systematic review. Ann Plast Surg. 2013;70(5):587–94.
Lattari V, Jones LM, Varcelotti JR, et al. The use of a permanent dermal allograft in full-thickness burns of the hand and foot: a report of three cases. J Burn Care Rehabil. 1997;18:147–55.
Moerman E, Middelkoop E, Mackie D, et al. The temporary use of allograft for complicated wounds in plastic surgery. Burns. 2002;28:S13–5.
Cuono CB, Langdon R, Birchall N, et al. Composite autologous allogeneic skin replacement: development and clinical application. Plast Reconstr Surg. 1987;80(4):626–37.
Pianigiani E, Ierardi F, Mazzanti B, et al. Human de-epidermized dermis as a stem cell carrier. Transplant Proc. 2010;42:2244–6.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Tognetti, L. et al. (2020). Skin Bank Bioproducts: The Basics. In: Fimiani, M., Rubegni, P., Cinotti, E. (eds) Technology in Practical Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-030-45351-0_41
Download citation
DOI: https://doi.org/10.1007/978-3-030-45351-0_41
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-45350-3
Online ISBN: 978-3-030-45351-0
eBook Packages: MedicineMedicine (R0)